QNTM Latest Press Releases

-- February 19, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM PRNewswire 7:29 PM

-- February 17, 2026 --

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors Globe Newswire 1:55 PM

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM Globe Newswire 12:59 PM

Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors Globe Newswire 9:41 AM

-- February 12, 2026 --

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM PRNewswire 4:02 PM

-- February 10, 2026 --

Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors Globe Newswire 9:00 AM

-- February 3, 2026 --

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM Globe Newswire 1:12 PM

-- February 2, 2026 --

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors Globe Newswire 10:46 AM

-- January 29, 2026 --

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM PRNewswire 10:00 AM

-- January 27, 2026 --

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM Globe Newswire 1:42 PM

-- January 26, 2026 --

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors Globe Newswire 9:26 AM

-- January 22, 2026 --

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM PRNewswire 10:00 AM

-- January 15, 2026 --

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM PRNewswire 10:00 AM

-- January 13, 2026 --

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM Globe Newswire 3:49 PM

-- December 26, 2025 --

Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm PRNewswire 12:00 PM

-- December 25, 2025 --

Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm Globe Newswire 12:00 PM

-- December 23, 2025 --

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) Globe Newswire 8:00 AM

-- December 22, 2025 --

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares ACCESS Newswire 9:00 AM

-- December 19, 2025 --

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares Globe Newswire 4:52 PM

-- December 1, 2025 --

Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC Globe Newswire 7:00 AM

-- November 28, 2025 --

REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC Globe Newswire 9:30 AM

-- November 27, 2025 --

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC Globe Newswire 4:00 PM

-- November 25, 2025 --

Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5 Globe Newswire 4:00 PM

-- November 7, 2025 --

Quantum Biopharma Reports Strong Third Quarter Results Maintaining 'No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio Globe Newswire 7:00 AM

-- November 6, 2025 --

From Lab Bench to Blockchain: How Biotech is Reinventing Funding Yolowire 10:43 AM

-- October 31, 2025 --

Quantum BioPharma Ltd. Provides Corporate Update Globe Newswire 7:51 PM

-- October 23, 2025 --

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication Globe Newswire 8:15 AM

-- October 20, 2025 --

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend Globe Newswire 8:30 AM

-- October 14, 2025 --

Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group Globe Newswire 8:15 AM

-- October 9, 2025 --

Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QNTM Business Wire 6:00 PM

QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm Business Wire 5:40 PM

-- October 8, 2025 --

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock Globe Newswire 8:00 AM

-- October 7, 2025 --

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View ACCESS Newswire 11:00 AM

-- October 3, 2025 --

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case Globe Newswire 7:00 AM

-- October 2, 2025 --

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial Globe Newswire 7:57 AM

-- October 1, 2025 --

Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials Globe Newswire 7:50 AM

-- September 29, 2025 --

Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders Globe Newswire 7:40 AM